Overview
Mantle Cell Lymphoma (MCL) is a rare and aggressive form of B-cell lymphoma, however, recent treatment advances in including rituximab and BTK inhibitors have improved outcomes. Specific genetic alterations like TP53 mutations or deletion 17p (del17p) have previously been correlated with poorer treatment response and outcomes. However, prior studies included fewer patients with both del17p and TP53 mutations (biallelic alterations).
This study aims to provide additional information on the impact of TP53 mutations and del17p, examining different subgroups of TP53 and del17p alterations, with particular focus on the biallelic alterations subgroup. Utilizing data from the Flatiron Health Research Database, researchers analyzed over 5,000 MCL patients and found that patients with biallelic alterations had poorer real-world overall survival (rwOS) compared to those with one or no alterations.
Why this matters
Recognizing genetic markers that influence prognosis can guide personalized treatment strategies, potentially improving outcomes for patients with mantle cell lymphoma. This study is the first to show numerically inferior rwOS in MCL patients with biallelic alterations compared to those with only one or neither abnormality, based on a large real-world cohort. These findings support early genetic testing to identify high-risk patients and underscore the need to prioritize newer therapies for those with biallelic alterations due to their poorer prognosis.